Literature DB >> 24817173

Evaluation of degradation kinetics and physicochemical stability of tenofovir.

Vivek Agrahari1, Sandeep Putty, Christiane Mathes, James B Murowchick, Bi-Botti C Youan.   

Abstract

Tenofovir (TFV) has been proven to prevent the transmission of the Human Immunodeficiency Virus (HIV) through the vagina. But, there is little information available about its stability under various storage and stress conditions. Hence, this study aimed to investigate the degradation behavior and physicochemical stability of TFV using liquid chromatography coupled mass spectrometry (LC-MS) and solid state X-ray diffraction (XRD) analyses. The LC-MS analysis was performed on a QTrap mass spectrometer with an enhanced mass spectrum (EMS) scan in positive mode. A reversed phase C18 column was used as the stationary phase. TFV exhibited degradation under acidic and alkaline hydrolytic conditions. The degradation products with m/z 289.2 and 170 amu have been proposed as 6-Hydroxy adenine derivative of TFV, and (2-hydroxypropan-2-yloxy) methylphosphonic acid, respectively. A pseudo-first-order degradation kinetic allowed for estimating the shelf-life, half-life, and time required for 90% degradation of 3.84, 25.34, and 84.22 h in acidic conditions, and 58.26, 384.49, and 1277.75 h in alkaline conditions, respectively. No significant degradation was observed at pH 4.5 (normal cervicovaginal pH) and oxidative stress conditions of 3% and 30% v/v hydrogen peroxide solutions. The shelf life of TFV powder at room temperature was 23 months as calculated by using an Arrhenius plot. The XRD pattern showed that the drug was stable and maintained its original crystallinity under the accelerated and thermal stress conditions applied. Stability analyses revealed that the TFV was stable in various stress conditions; however, formulation strategies should be implemented to protect it in strong acidic and alkaline environments.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Arrhenius plot; degradation kinetic; forced degradation; tenofovir

Mesh:

Substances:

Year:  2014        PMID: 24817173      PMCID: PMC4278957          DOI: 10.1002/dta.1656

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  33 in total

1.  The ICH guidance in practice: stress degradation studies on ornidazole and development of a validated stability-indicating assay.

Authors:  M Bakshi; B Singh; A Singh; S Singh
Journal:  J Pharm Biomed Anal       Date:  2001-12       Impact factor: 3.935

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS.

Authors:  Tom Delahunty; Lane Bushman; Courtney V Fletcher
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-11-02       Impact factor: 3.205

4.  Strategy for identification and characterization of small quantities of drug degradation products using LC and LC-MS: application to valsartan, a model drug.

Authors:  Surbhi Mehta; Ravi P Shah; Saranjit Singh
Journal:  Drug Test Anal       Date:  2010-02       Impact factor: 3.345

5.  Rapid and specific liquid chromatographic tandem mass spectrometric determination of tenofovir in human plasma and its fragmentation study.

Authors:  Manish Yadav; Tulsidas Mishra; Puran Singhal; Sailendra Goswami; Pranav S Shrivastav
Journal:  J Chromatogr Sci       Date:  2009-02       Impact factor: 1.618

6.  A kinetic study of the polymorphic transformation of nimodipine and indomethacin during high shear granulation.

Authors:  Zhen Guo; Mingxin Ma; Tianyi Wang; Di Chang; Tongying Jiang; Siling Wang
Journal:  AAPS PharmSciTech       Date:  2011-05-07       Impact factor: 3.246

7.  A study of the prevalence of hydrogen peroxide generating Lactobacilli in bacterial vaginosis: the determination of H2O2 concentrations generated, in vitro , by isolated strains and the levels found in vaginal secretions of women with and without infection.

Authors:  S Al-Mushrif; B M Jones
Journal:  J Obstet Gynaecol       Date:  1998-01       Impact factor: 1.246

8.  In vitro profiling of the vaginal permeation potential of anti-HIV microbicides and the influence of formulation excipients.

Authors:  Carolien Grammen; Patrick Augustijns; Joachim Brouwers
Journal:  Antiviral Res       Date:  2012-09-20       Impact factor: 5.970

9.  Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection.

Authors:  Vincent Jullien; Jean-Marc Tréluyer; Gérard Pons; Elisabeth Rey
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-03-05       Impact factor: 3.205

10.  A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.

Authors:  Antonio D'Avolio; Mauro Sciandra; Marco Siccardi; Lorena Baietto; Daniel Gonzalez de Requena; Stefano Bonora; Giovanni Di Perri
Journal:  J Chromatogr Sci       Date:  2008-07       Impact factor: 1.618

View more
  7 in total

1.  Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro.

Authors:  Kevin M Tyo; Hung R Vuong; Danial A Malik; Lee B Sims; Houda Alatassi; Jinghua Duan; Walter H Watson; Jill M Steinbach-Rankins
Journal:  Int J Pharm       Date:  2017-08-07       Impact factor: 5.875

2.  Real-Time Analysis of Tenofovir Release Kinetics Using Quantitative Phosphorus (31P) Nuclear Magnetic Resonance Spectroscopy.

Authors:  Vivek Agrahari; Jianing Meng; Sudhaunshu S Purohit; Nathan A Oyler; Bi-Botti C Youan
Journal:  J Pharm Sci       Date:  2017-04-13       Impact factor: 3.534

3.  A Mechanistic In Vivo/Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention.

Authors:  Priya Jayachandran; Maria Garcia-Cremades; Katarina Vučićević; Namandjé N Bumpus; Peter Anton; Craig Hendrix; Radojka Savić
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-02-06

4.  Encapsulation, release and insecticidal activity of Pongamia pinnata (L.) seed oil.

Authors:  Aloke Purkait; Ayan Mukherjee; Dipak Kumar Hazra; Kusal Roy; Pabitra Kumar Biswas; Ramen Kumar Kole
Journal:  Heliyon       Date:  2021-03-24

Review 5.  Application of Sol-Gels for Treatment of Gynaecological Conditions-Physiological Perspectives and Emerging Concepts in Intravaginal Drug Delivery.

Authors:  Ritu Thapa; Shila Gurung; Marie-Odile Parat; Harendra S Parekh; Preeti Pandey
Journal:  Gels       Date:  2022-02-08

6.  Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue.

Authors:  Laura Else; Sujan D Penchala; Azure-Dee Pillay; Thabiso B Seiphetlo; Limakatso Lebina; Christian Callebaut; Suks Minhas; Roland Morley; Tina Rashid; Neil Martinson; Julie Fox; Saye Khoo; Carolina Herrera
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

7.  Degradation kinetics of artesunate for the development of an ex-tempore intravenous injection.

Authors:  Fanta Gashe; Evelien Wynendaele; Bart De Spiegeleer; Sultan Suleman
Journal:  Malar J       Date:  2022-09-06       Impact factor: 3.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.